Bladder Cancer - Results from #80

Cost comparison between open radical cystectomy, laparoscopic radical cystectomy, and robot-assisted radical cystectomy for patients with bladder cancer: a systematic review of segmental costs. November 12, 2019

Systemic immune-inflammation index predicts prognosis of bladder cancer patients after radical cystectomy. November 12, 2019

Patients' self-report anxiety, depression and quality of life and their predictive factors in muscle invasive bladder cancer patients receiving adjuvant chemotherapy. November 12, 2019

Monthly Maintenance Intravesical Combination Gemcitabine/Docetaxel for Non Muscle-invasive Bladder Cancer - Expert Commentary November 11, 2019

Bladder Cancer Outcomes in Women Vary over Time - Expert Commentary November 11, 2019

Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. November 11, 2019

Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations. November 11, 2019

Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies. November 11, 2019

External Replication of Urinary Bladder Cancer Prognostic Polymorphisms in the UK Biobank. November 8, 2019

Screening logs from a pilot randomized controlled trial of radical cystectomy versus chemoradiation therapy for muscle-invasive bladder cancer. November 8, 2019

The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. November 8, 2019

Long Non-coding RNAs Identify A Subset of Luminal Muscle-invasive Bladder Cancer Patients with Favorable Prognosis November 7, 2019

Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis. November 7, 2019

Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM). November 7, 2019

Novel Biomarkers Associated With Progression and Prognosis of Bladder Cancer Identified by Co-expression Analysis. November 6, 2019

The global burden of urinary bladder cancer: an update. November 6, 2019

A Case for Risk-adapted Management of Low-grade Bladder Tumors. November 6, 2019

WNT/β-catenin signaling in urothelial carcinoma of bladder. November 5, 2019

Prognostic utility of the combination of pretreatment monocyte-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with NMIBC after transurethral resection. November 5, 2019

A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera. November 5, 2019

Page 5 of 320